Virginia is currently home to 1837 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Recruiting
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Urology of Virginia (UVA) - Virginia Beach (Devine-Tidewater Urology), Virginia Beach, Virginia
Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Study of AVZO-021 in Patients With Advanced Solid Tumors
Recruiting
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Recruiting
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of divarasib combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Oncology & Hematology Associates of Southwest Virginia, Inc, Blacksburg, Virginia
Conditions: Non-Small Cell Lung Cancer
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Recruiting
Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Breast Cancer, Solid Tumors, Adult
Simplified Post Op Rehabilitation for Ankle and Pilon Fractures
Recruiting
The aim of this study is to compare standard post operative rehabilitation with a simplified wooden block stretching protocol that will yield similar results.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/23/2025
Locations: University of Virginia Medical Center, Charlottesville, Virginia
Conditions: Ankle Fractures, Pilon Fracture
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
Recruiting
This a Phase 3, prospective, open-label, multicenter study of \[15-O\]-H2O injection for PET imaging of subjects with suspected CAD. Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study at approximately 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled to account for an estimated 15% drop-out rate. Screening assessments will occur prior to enrollment to confirm eligibility. All participants wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University of Virginia Medical Center, Charlottesville, Virginia
Conditions: Coronary Artery Disease
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Recruiting
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Virginia Oncology Associates, Norfolk, Virginia
Conditions: Relapsed and/or Refractory B-cell Lymphoma
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Recruiting
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University of Virginia Cancer Center, Charlottesville, Virginia
Conditions: Myelofibrosis
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Recruiting
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
05/22/2025
Locations: Piedmont Eye Center, Lynchburg, Virginia
Conditions: Geographic Atrophy, Macular Degeneration
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
Recruiting
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Charlottesville Medical Research Center, LLC, Charlottesville, Virginia
Conditions: Acute Gastroenteritis, Norovirus Acute Gastroenteritis
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
Recruiting
The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
05/22/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Preclinical Alzheimer's Disease
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
Recruiting
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related taste changes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia
Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma